Christopher Michaeles, MD
Cardiovascular Disease · Olean, NYNPI 1225060684
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,892 of the $3,106 with a category attached, or 60.9%. 11 manufacturers reported payments, led by Medtronic at 43.2% of the total. Reporting peaked in 2022 at $2,695 and has fallen 94.7% since, to $142 in 2024.
Across 38 payments — averaging $81.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Edwards Lifesciences$1K
- Boston Scientific$144
- Abiomed$141
- Abbott$78
- Kestra Medical Technology Services, Inc.$36
- plus $106 from 5 others
Across 2 payments — averaging $50,001 each. An ownership or investment interest held by the physician or an immediate family member.
- Seigla Medical, Inc.$100K
What the payments were for
- Travel & lodging$1,89261%
- Food & beverage$1,21339%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $1,341 |
| Edwards Lifesciences | 11 | $1,261 |
| Boston Scientific | 2 | $144 |
| Abiomed | 2 | $141 |
| Abbott | 2 | $78 |
| Kestra Medical Technology Services, Inc. | 1 | $36 |
| Lantheus Medical Imaging, Inc. | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| AstraZeneca | 1 | $18 |
| Pfizer | 1 | $18 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,106 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 16 | $14,553 |
| Metoprolol Succinate | 16 | $461 |
| ClopidogrelClopidogrel Bisulfate | 11 | $318 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Olean
- Joseph GomezOlean$185K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.